NUS

Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore Receive HSA Approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer

Retrieved on: 
Wednesday, August 2, 2023
Research, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, General Health, Science, Oncology, NICS, Nephrotoxicity, Prevalence, GBM, Half-life, National University of Singapore, National university, Glomus tumor, Safety, Hope, CTA, Multimedia, NSCLC, Lung cancer, HTC, Glioblastoma, Death, Carcinoma, Serum albumin, MD, NCIS, Patient, PRRT, Outline of health sciences, Cancer, SSTR2, Neoplasm, NPC, MTCS, Health Sciences Authority, HSA, NUS, Pharmaceutical industry, Medical imaging

Molecular Targeting Technologies, Inc. (MTTI), and its wholly owned subsidiary, Molecular Theranostic Center of Singapore (MTCS), announced the approval of a Clinical Trial Authorization (CTA) application by the Health Sciences Authority (HSA) of Singapore.

Key Points: 
  • Molecular Targeting Technologies, Inc. (MTTI), and its wholly owned subsidiary, Molecular Theranostic Center of Singapore (MTCS), announced the approval of a Clinical Trial Authorization (CTA) application by the Health Sciences Authority (HSA) of Singapore.
  • View the full release here: https://www.businesswire.com/news/home/20230802243597/en/
    Somatostatin receptor 2 (SSTR2) is found in 81% of primary, recurrent, and metastatic NPC patients.
  • A recent three-year clinical trial follow-up* showed EBTATE was effective at controlling tumor and well tolerated without serious adverse events or nephrotoxicity.
  • MTTI’s products include: EBTATE (neuroendocrine tumors (“NET”); Hürthle thyroid cancer (HTC), and nasopharyngeal cancer (NPC); EBRGD for non-small cell lung cancer (NSCLC) and glioblastoma (GBM).

Nu Skin Enterprises Appoints James D. Thomas as Chief Financial Officer

Retrieved on: 
Thursday, July 27, 2023
PwC, CFO, Nu Skin Enterprises, Beauty, NYSE, NUS, Utah State University, Management, Science

PROVO, Utah, July 27, 2023 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced the appointment of James D. Thomas as executive vice president and chief financial officer.

Key Points: 
  • PROVO, Utah, July 27, 2023 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced the appointment of James D. Thomas as executive vice president and chief financial officer.
  • Thomas has been serving as interim CFO for the past four months and has been the company's chief accounting officer for the past four years.
  • Thomas joined Nu Skin in 2010 and has served as interim chief financial officer since April 2023 and as chief accounting officer since 2019.
  • Prior to Nu Skin, Thomas worked as an assistant controller of another public, technology-enabled wellness company and served in the assurance practice at PricewaterhouseCoopers LLP.

Data Center Cooling Market to Reach USD 12.64 Billion Year-Over-Year by 2028, A USD 65 Billion Opportunity Over the Next 6 Years- Arizton

Retrieved on: 
Thursday, July 13, 2023
Digital Realty, NTU, ASHRAE, Carbon footprint, National University of Singapore, National university, CRAC, CoreSite, Kilowatt-hour, Equinix, CyrusOne, Cargill, Investment, Immersion, OPEX, Growth, Government, NTT, Nanyang Technological University, NUS, Heating, ventilation, and air conditioning, Renewable energy

Data centers follow cooling standards that dictate the design, adoption, and operation of cooling systems and equipment to ensure optimal cooling.

Key Points: 
  • Data centers follow cooling standards that dictate the design, adoption, and operation of cooling systems and equipment to ensure optimal cooling.
  • Hybrid liquid cooling, plant-based immersion cooling, waterless cooling, and river water cooling are some of the efficient solutions in the data center cooling market that operators are considering reducing their CAPEX and OPEX.
  • CRAC and CRAH units dominate the cooling systems market, accounting for around 35% of the overall data center cooling market share.
  • North America also leads the global data center cooling market, dominated by the US, followed by Canada, with investments in billions by colocation providers, hyperscale data center operators, enterprises, and government agencies in data center facilities and adopting redundant power backup infrastructure.

Data Center Cooling Market to Reach USD 12.64 Billion Year-Over-Year by 2028, A USD 65 Billion Opportunity Over the Next 6 Years- Arizton

Retrieved on: 
Thursday, July 13, 2023
Digital Realty, NTU, ASHRAE, Carbon footprint, National University of Singapore, National university, CRAC, CoreSite, Kilowatt-hour, Equinix, CyrusOne, Cargill, Investment, Immersion, OPEX, Growth, Government, NTT, Nanyang Technological University, NUS, Heating, ventilation, and air conditioning, Renewable energy

Data centers follow cooling standards that dictate the design, adoption, and operation of cooling systems and equipment to ensure optimal cooling.

Key Points: 
  • Data centers follow cooling standards that dictate the design, adoption, and operation of cooling systems and equipment to ensure optimal cooling.
  • Hybrid liquid cooling, plant-based immersion cooling, waterless cooling, and river water cooling are some of the efficient solutions in the data center cooling market that operators are considering reducing their CAPEX and OPEX.
  • CRAC and CRAH units dominate the cooling systems market, accounting for around 35% of the overall data center cooling market share.
  • North America also leads the global data center cooling market, dominated by the US, followed by Canada, with investments in billions by colocation providers, hyperscale data center operators, enterprises, and government agencies in data center facilities and adopting redundant power backup infrastructure.

Northern Trust, NUS School of Computing and NUS Asian Institute of Digital Finance Join Forces to Support Blockchain Development for Institutional Use

Retrieved on: 
Wednesday, July 12, 2023
Technology, Finance, Fintech, Banking, Professional Services, Digital Cash Management, Digital Assets, Blockchain, Asset Management, Web3, Partnership, Market, National university, Risk assessment, Trust, Intelligence, Research, Digital asset, Regulatory technology, Memorandum of understanding, Asian Institute of Digital Finance, Faculty, Government, NUS, Cryptocurrency, Northern Trust

Northern Trust (Nasdaq: NTRS), the National University of Singapore’s School of Computing (NUS Computing) and Asian Institute of Digital Finance (NUS AIDF) today announced a series of research and industry development initiatives that will advance efforts to define the future of blockchain for institutional investors.

Key Points: 
  • Northern Trust (Nasdaq: NTRS), the National University of Singapore’s School of Computing (NUS Computing) and Asian Institute of Digital Finance (NUS AIDF) today announced a series of research and industry development initiatives that will advance efforts to define the future of blockchain for institutional investors.
  • The research is part of the Singapore Blockchain Innovation Programme (SBIP), a national-level partnership anchored at NUS Computing to explore institutional use of blockchain and the translation of new technology for the banking industry.
  • A memorandum of understanding (MoU) with NUS AIDF, a university-level institute in NUS.
  • An agreement between Northern Trust and NUS Computing to provide an industry-linked internship opportunity to a student in the Master of Digital Fintech program.

Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

Retrieved on: 
Tuesday, July 11, 2023
MBBS, National University of Singapore, National university, Principal investigator, Receptor (biochemistry), Clinical trial, Cancer, Research, Radiology, Doctor of Philosophy, Nuclear medicine, MD, Patient, ASTS, Immunohistochemistry, Therapy, NUS, CSI, Medical device, Medical imaging

WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today announced a collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to evaluate radiopharmaceutical versions of MNPR-101 in several aggressive cancers.

Key Points: 
  • WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today announced a collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to evaluate radiopharmaceutical versions of MNPR-101 in several aggressive cancers.
  • Dr. Anand Jeyasekharan, MBBS MRCP (UK) PhD, of CSI Singapore, NUS, will be the Principal Investigator on the collaboration.
  • In this collaboration, Dr. Jeyasekharan will initially investigate uPAR expression levels in tissue samples from patients with various subtypes of advanced soft tissue sarcoma (ASTS).
  • Studies have shown uPAR to be a promising target for ASTS, which is a cancer Dr. Jeyasekharan specializes in treating.

Nu Skin Enterprises to Announce Second Quarter 2023 Financial Results

Retrieved on: 
Monday, July 10, 2023
Nu Skin Enterprises, Webcast, NYSE, NUS, Mobile phone, Cryptocurrency

PROVO, Utah, July 10, 2023 (GLOBE NEWSWIRE) -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced it will release second quarter 2023 results after the market closes on Tuesday, Aug. 1.

Key Points: 
  • PROVO, Utah, July 10, 2023 (GLOBE NEWSWIRE) -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced it will release second quarter 2023 results after the market closes on Tuesday, Aug. 1.
  • The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m.
  • During the call, management will discuss recent results and upcoming business initiatives.
  • The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company’s website at ir.nuskin.com.

Innovative paper-like, battery-free, AI-enabled sensor for holistic wound monitoring

Retrieved on: 
Tuesday, June 27, 2023
Science and technology in Asia, Infection, Science, PETAL, Nanyang Technological University, Science Advances, National University of Singapore, Electronics, Classification, Oxygen, Glucose, Multiplexing, National university, Scar, Research, Temperature, Multimedia, Burn, Biomarker, Interleukin 6, Yale-NUS College, Pain, Uric acid, Hospital, Patient, A*STAR, Algorithm, Artificial intelligence, AI, Trauma, PH, NUS, Skin, Wound healing, Nursing, Medical imaging, Instrumentation, Engineering

SINGAPORE, June 27, 2023 /PRNewswire/ -- Timely and effective monitoring of wound healing status is critical to wound care and management.

Key Points: 
  • SINGAPORE, June 27, 2023 /PRNewswire/ -- Timely and effective monitoring of wound healing status is critical to wound care and management.
  • Wound infections are mostly diagnosed via swabbing followed by a bacteria culture which involves long waiting time and does not provide timely wound diagnosis.
  • These biomarkers were carefully selected to effectively assess wound inflammation, infection as well as the condition of the wound environment.
  • The bottom wound contact layer gently attaches the sensor patch to the skin and protects the wound bed from direct contact with the sensor panel, to minimise wound tissue disruptions.

LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore

Retrieved on: 
Monday, June 26, 2023
Exercise, Medical school, National university, New Drug Application, Quality of life, Oxford Handbook of Clinical Medicine, National University of Singapore, Assistant professor, Patient, Heart failure, HCM, NUS, Pharmaceutical industry

“The approval of CAMZYOS in Singapore brings a much needed, effective new treatment option to our local oHCM patients.”

Key Points: 
  • “The approval of CAMZYOS in Singapore brings a much needed, effective new treatment option to our local oHCM patients.”
    Marketing approval in Singapore was based on data from the Phase 3 EXPLORER-HCM trial.
  • "LianBio is committed to bringing mavacamten to symptomatic oHCM patients in Asia,” said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio.
  • “Mavacamten is now approved in both Singapore and Macau, with additional New Drug Applications on file in Mainland China and Hong Kong.
  • We look forward to continuing to work with regulators in the region to accelerate access to this promising new therapeutic option for patients in need.”

Perovskite solar cells invented by NUS scientists set new world record for power conversion efficiency

Retrieved on: 
Thursday, June 22, 2023
Progress in Photovoltaics, Engineering, National University of Singapore, National university, National Renewable Energy Laboratory, Perovskite, Research, Yale-NUS College, Longevity, Benchmarking, NUS, Renewable energy, Industrial design

SINGAPORE,  June 22, 2023 /PRNewswire/ -- Perovskite solar cells designed by a team of scientists from the National University of Singapore (NUS) have attained a world record efficiency of 24.35% with an active area of 1 cm2. This achievement paves the way for cheaper, more efficient and durable solar cells.

Key Points: 
  • Prior to the record-breaking feat by the NUS team, the best 1-cm2 perovskite solar cell recorded a power conversion efficiency of 23.7%.
  • "To address this challenge, we undertook a dedicated effort to develop innovative and scalable technologies aimed at improving the efficiency of 1-cm2 perovskite solar cells.
  • He added, "Building on more than 14 years of perovskite solar cell development, this work represents the first instance of an inverted-structure perovskite solar cell exceeding the normal structured perovskite solar cells with an active area of 1 cm2, and this is mainly attributed to the innovative charge transporting material incorporated in our perovskite solar cells.
  • Since inverted-structure perovskite solar cells always offer excellent stability and scalability, achieving a higher efficiency than for normal-structured perovskite cells represents a significant milestone in commercialising this cutting-edge technology."